Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

944 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Nifedipine retard was as effective as angiotensin converting enzyme inhibitors in preventing cardiac events in high-risk hypertensive patients with diabetes and coronary artery disease: the Japan Multicenter Investigation for Cardiovascular Diseases-B (JMIC-B) subgroup analysis.
Yui Y, Sumiyoshi T, Kodama K, Hirayama A, Nonogi H, Kanmatsuse K, Origasa H, Iimura O, Ishii M, Saruta T, Arakawa K, Hosoda S, Kawai C. Yui Y, et al. Among authors: sumiyoshi t. Hypertens Res. 2004 Jul;27(7):449-56. doi: 10.1291/hypres.27.449. Hypertens Res. 2004. PMID: 15302980 Free article. Clinical Trial.
Effect of trapidil on cardiovascular events in patients with coronary artery disease (results from the Japan Multicenter Investigation for Cardiovascular Diseases-Mochida [JMIC-M]).
Hirayama A, Kodama K, Yui Y, Nonogi H, Sumiyoshi T, Origasa H, Hosoda S, Kawai C; Japan Multicenter Investigation for Cardiovascular Diseases-Mochida Investigators. Hirayama A, et al. Among authors: sumiyoshi t. Am J Cardiol. 2003 Oct 1;92(7):789-93. doi: 10.1016/s0002-9149(03)00884-1. Am J Cardiol. 2003. PMID: 14516877 Clinical Trial.
Comparison of nifedipine retard with angiotensin converting enzyme inhibitors in Japanese hypertensive patients with coronary artery disease: the Japan Multicenter Investigation for Cardiovascular Diseases-B (JMIC-B) randomized trial.
Yui Y, Sumiyoshi T, Kodama K, Hirayama A, Nonogi H, Kanmatsuse K, Origasa H, Iimura O, Ishii M, Saruta T, Arakawa K, Hosoda S, Kawai C; Japan Multicenter Investigation for Cardiovascular Diseases-B Study Group. Yui Y, et al. Among authors: sumiyoshi t. Hypertens Res. 2004 Mar;27(3):181-91. doi: 10.1291/hypres.27.181. Hypertens Res. 2004. PMID: 15080377 Free article. Clinical Trial.
Quantitative coronary angiogram analysis: nifedipine retard versus angiotensin-converting enzyme inhibitors (JMIC-B side arm study).
Shinoda E, Yui Y, Kodama K, Hirayama A, Nonogi H, Haze K, Sumiyoshi T, Hosoda S, Kawai C; Japan Multicenter Investigation for Cardiovascular Diseases-B Study Group. Shinoda E, et al. Among authors: sumiyoshi t. Hypertension. 2005 Jun;45(6):1153-8. doi: 10.1161/01.HYP.0000165677.71421.8c. Epub 2005 Apr 25. Hypertension. 2005. PMID: 15851624
Nifedipine retard prevents hospitalization for angina pectoris better than angiotensin-converting enzyme inhibitors in hypertensive Japanese patients with previous myocardial infarction (JMIC-B substudy).
Yui Y, Shinoda E, Kodama K, Hirayama A, Nonogi H, Haze K, Sumiyoshi T, Hosoda S, Kawai C; Japan Multicenter Investigation for Cardiovascular Diseases B (JMIC-B) Study Group. Yui Y, et al. Among authors: sumiyoshi t. J Hypertens. 2007 Oct;25(10):2019-26. doi: 10.1097/HJH.0b013e32829c6908. J Hypertens. 2007. PMID: 17885543 Clinical Trial.
Reverse remodeling and improved function by antihypertensive treatment in hypertensive patients with coronary artery disease.
Yui Y, Kodama K, Hirayama A, Nishio R, Iwanaga Y, Nonogi H, Haze K, Sumiyoshi T, Yui N, Hosoda S, Kawai C; Japan Multicenter Investigation for Cardiovascular Diseases B (JMIC-B) Study Group. Yui Y, et al. Among authors: sumiyoshi t. J Hypertens. 2010 Jan;28(1):178-85. doi: 10.1097/HJH.0b013e3283324668. J Hypertens. 2010. PMID: 19927011 Clinical Trial.
Angiotensin receptor blocker-based therapy and cardiovascular events in hypertensive patients with coronary artery disease and impaired renal function.
Shiga T, Kasanuki H, Hagiwara N, Sumiyoshi T, Honda T, Haze K, Takagi A, Kawana M, Origasa H, Ogawa H; Heart Institute of Japan Candesartan Randomized Trial for Evaluation in Coronary Artery Disease (Hij-Create) Investigators. Shiga T, et al. Among authors: sumiyoshi t. Blood Press. 2010 Dec;19(6):359-65. doi: 10.3109/08037051003802475. Epub 2010 May 24. Blood Press. 2010. PMID: 20491606 Free article. Clinical Trial.
Angiotensin II receptor blocker-based vs. non-angiotensin II receptor blocker-based therapy in patients with angiographically documented coronary artery disease and hypertension: the Heart Institute of Japan Candesartan Randomized Trial for Evaluation in Coronary Artery Disease (HIJ-CREATE).
Kasanuki H, Hagiwara N, Hosoda S, Sumiyoshi T, Honda T, Haze K, Nagashima M, Yamaguchi J, Origasa H, Urashima M, Ogawa H; HIJ-CREATE Investigators. Kasanuki H, et al. Among authors: sumiyoshi t. Eur Heart J. 2009 May;30(10):1203-12. doi: 10.1093/eurheartj/ehp101. Epub 2009 Apr 4. Eur Heart J. 2009. PMID: 19346521 Clinical Trial.
944 results